

MaxCyte Inc (MXCT) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/MB479AFEEA9DEN.html>

Date: July 2021

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: MB479AFEEA9DEN

Abstracts

MaxCyte Inc (MXCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MaxCyte Inc (MaxCyte) discovers, manufactures and commercializes cell-based medicines. The company's products include MaxCyte STX, MaxCyte VLX, MaxCyte GT, ExPERTATx, ExPERTGTx, ExPERTSTx, and ExPERTVLx scalable transfection systems, which use the flow electroporation technology for engineering of cells. It is investigating MCY-M11 IP, a mesothelin targeted therapy for treating ovarian and peritoneal mesothelioma; and MCY-M11 IV therapy for undisclosed solid tumors. MaxCyte provides insourcing services such as instrument training, follow-on experimentation and others. The company developed CARMA, a proprietary technology platform for the evolution of chimeric antigen receptor (CAR) immune cell therapies based on non-viral, human messenger RNA (mRNA), and its ExPERT platform facilitates complex cellular engineering to enable the next generation of cellular therapies, which allow molecules to be gently, consistently, and repeatably inserted into cells for specific purposes. Its products are used for designing functional cell-based assays, protein and antibody expression, stable cell line development, viral vector production, gene editing and cell and gene therapies. MaxCyte is headquartered in Gaithersburg, Maryland, the US.

MaxCyte Inc Key Recent Developments

Jul 12,2021: Financial information in the Form S-1 registration statement and Change to Board of Directors

Jul 12,2021: MAXCYTE: S-1 financial information & Directorate change

Jun 16,2021: MaxCyte announce Publication of Annual Report and Accounts

Jun 15,2021: MaxCyte Adds Two New Non-Executive Directors to Its Board

Jun 15,2021: MaxCyte Appoints Two New Non-Executive Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

MaxCyte Inc - Key Facts
MaxCyte Inc - Key Employees
MaxCyte Inc - Key Employee Biographies
MaxCyte Inc - Major Products and Services
MaxCyte Inc - History
MaxCyte Inc - Company Statement
MaxCyte Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
MaxCyte Inc - Business Description
R&D Overview
MaxCyte Inc - Corporate Strategy
MaxCyte Inc - SWOT Analysis
SWOT Analysis - Overview
MaxCyte Inc - Strengths
MaxCyte Inc - Weaknesses
MaxCyte Inc - Opportunities
MaxCyte Inc - Threats
MaxCyte Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MaxCyte Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 12, 2021: Financial information in the Form S-1 registration statement and Change to Board of Directors

Jul 12, 2021: MAXCYTE: S-1 financial information & Directorate change

Jun 16, 2021: MaxCyte announce Publication of Annual Report and Accounts

Jun 15, 2021: MaxCyte Adds Two New Non-Executive Directors to Its Board

Jun 15, 2021: MaxCyte Appoints Two New Non-Executive Directors

Apr 20, 2021: MaxCyte reports final results for the year ended 31 December 2020

Feb 23, 2021: MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences

Dec 23, 2020: MaxCyte: Trading update

Oct 13, 2020: MaxCyte Bolsters leadership team with promotion of Brad Calvin to Chief Commercial Officer and new key VP appointments

Sep 21, 2020: MaxCyte : Results for the Six Months ended 30 June 2020

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

MaxCyte Inc, Key Facts
MaxCyte Inc, Key Employees
MaxCyte Inc, Key Employee Biographies
MaxCyte Inc, Major Products and Services
MaxCyte Inc, History
MaxCyte Inc, Other Locations
MaxCyte Inc, Subsidiaries
MaxCyte Inc, Key Competitors
MaxCyte Inc, Ratios based on current share price
MaxCyte Inc, Annual Ratios
MaxCyte Inc, Annual Ratios (Cont...1)
MaxCyte Inc, Interim Ratios
MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MaxCyte Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

MaxCyte Inc, Performance Chart (2016 - 2020)

MaxCyte Inc, Ratio Charts

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: MaxCyte Inc (MXCT) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/MB479AFEEA9DEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MB479AFEEA9DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970